TCT-393 A randomized trial comparing two vascular closure devices: PROGLIDE and the novel EXOSEAL after percutaneous femoral procedures

Abstract

includes cardiogenic shock in 18 patients (38%) and postcardiotomy cardiogenic shock in 29 patients (62%). Thirty-eight patients of the 47 total patients (80%) were supported withImpella 5.0/LD and with Impella 2.5 for the remaining 9 (19%) patients. . The 30-day survival rate was 75% (35/47) and of those 97% (34/35) recovered their native heart function and 1 (3%) was bridged to long term ventricular assist device Complications occurred in 14 (30%) patients and consisted of device malfunction (11%), high purge pressures (6%), catheter fracture (2%), and groin hematoma (2%). Conclusions: The outcomes from our study were very favorable; myocardial recovery was accomplished in the majority of the patients with acceptable complication rate in these critically ill patients. These benefits encourage the use of a less invasive circulatory support with Impella in the setting of cardiogenic shock.

Network Meta-analysis of Randomized Trials on the Safety of Vascular Closure Devices for Femoral Arterial Puncture Site Haemostasis

“…The reasons for exclusion were mainly duplicate publication, unrelated topics, retrospective studies, meta-analysis, non-comparative or non-random design studies, and studies without appropriate control groups or outcome measurements. In addition, two eligible trials 8 11 for which the full text was not available were excluded. Two trials 12 13 were further excluded due to zero events in both arms.…”

“…Recently, several more prospective, randomized trials have evaluated the efficacy and safety of VCDs 6 7 8 . In addition, new generations of various VCDs have been designed and applied clinically 7 .…”